AGM/EGMJun 4, 2026, 04:32 PM
Sarepta Stockholders Approve New Equity & Stock Purchase Plans
AI Summary
Sarepta Therapeutics' stockholders approved the 2026 Equity Incentive Plan, authorizing 6,286,841 shares, and the 2026 Employee Stock Purchase Plan, authorizing 1,500,000 shares, at its Annual Meeting. Additionally, five Class I directors were elected, named executive officer compensation for 2025 received advisory approval, and KPMG LLP was ratified as the independent auditor for 2026.
Key Highlights
- Stockholders approved the 2026 Equity Incentive Plan, authorizing 6,286,841 shares of common stock.
- Stockholders approved the 2026 Employee Stock Purchase Plan, authorizing 1,500,000 shares of common stock.
- Five Class I directors were elected to the board for a two-year term.
- Named executive officer compensation for 2025 was approved on an advisory basis with 45,185,398 votes For.
- KPMG LLP was ratified as the independent registered public accounting firm for 2026 with 79,907,368 votes For.
- The Annual Meeting had a quorum of 77.97% of outstanding shares, representing 82,309,288 shares.
Price Impact
More from SRPT